Tag Archives: relapsed or refractory advance renal cell carcinoma
U.S. Food and Drug Administration Approves Tivozanib for Relapsed or Refractory Advanced RCC
According to a press release from AVEO Oncology, “On March 10’th, 2021, the FDA has granted approval to tivozanib (Fotivda), […]
